Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2006

View Archived Issues

ViroPharma reveals health initiatives to combat C. difficile-associated disease

MediVas reports promising data from preclinical H5N1 vaccine study

MMV, Genzyme and Broad Institute expand collaboration for malaria

Phase II study of atiprimod in advanced carcinoid patients opens

New program studies AVI-5126 for use in CABG

Closing of Cell Therapeutics' agreement with Novartis

Adjuvant phytotherapy for Parkinson's disease

FDA approval for Coreg CR

First selective KAT II inhibitor targeted for procognition presented at SfN

WBI-1001 for psoriasis completes key preclinical studies

Positive findings from pilot study of alkaline phosphatase in sepsis

New trial studies Alimta in extensive-stage small cell lung cancer

Jennerex and Green Cross sign agreement for JX-594 in Korea

Inhibition of TFFs causes regression of human breast cancers in animal models

NeuroSearch reports on a novel SK channel negative modulator

Novel antiobesity compounds from Prosidion avoid sympathetic-driven complications

Mechanisms underlying the anticonvulsant activity of alpha-substituted lactams

Recent patents cover novel immunomodulators

Recent Organon and Microbia patents report new therapeutic agents for metabolic disorders

Variations in endothelin-converting enzyme-like 1 gene linked to type 2 diabetes

Mutations in neuronal UCP genes may affect risk of schizophrenia

Approval for Reyataz 300 mg single capsule formulation

Approvable letter for Gestiva

Altana receives approval for ciclesonide nasal spray

MEFV found to be a disease susceptibility gene for IBD

Desonate approved for mild to moderate atopic dermatitis

Betaseron approved for use after first event suggestive of MS

Nonapprovable letter for faropenem medoxomil

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...